COVID-19 mRNA Vaccines Show Promise in Boosting Cancer Immunotherapy

A new study looks at the link between an mRNA vaccine and cancer immunotherapy, an unexpected finding now being studied further. For the bigger picture, read our plain-language guide to COVID-19.

The mRNA technology behind the COVID-19 vaccines that saved millions of lives during the pandemic may also help fight cancer, according to new research published in Nature. Scientists found that the Pfizer and Moderna mRNA vaccines can strengthen the immune system’s ability to recognize and kill tumor cells, even when the vaccines were originally designed to target the coronavirus — not cancer.

The study looked at more than 1,000 patients with advanced melanoma and lung cancer who were treated with immunotherapy drugs called immune checkpoint inhibitors. These drugs help the immune system attack tumors, but they don’t always work, especially on “cold” tumors that can hide from immune cells.

Remarkably, patients who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy were more than twice as likely to survive three years compared with those who didn’t get vaccinated. For patients whose tumors usually don’t respond to immunotherapy, survival improved nearly fivefold.

Animal studies suggest that the mRNA vaccines act like an alarm, activating the immune system and helping it recognize cancer cells that might otherwise go unnoticed. When combined with immune checkpoint inhibitors, the vaccines appear to unleash a stronger, more coordinated attack on tumors.

Researchers are now preparing a nationwide clinical trial to test this effect in lung cancer patients. If results hold up, mRNA vaccines — already safe, affordable, and widely available — could become a valuable addition to cancer treatment. See active studies on ClinicalTrials.gov.

What began as a breakthrough in fighting infectious disease might soon offer new hope against cancer, showing how innovations from the COVID-19 pandemic could continue saving lives in unexpected ways.

Read more on this story here.